Clinical significance of intrapulmonary lymph node dissection in pathological stage IA non-small cell lung cancer: A propensity score matching analysis

肺内淋巴结清扫术在病理IA期非小细胞肺癌中的临床意义:倾向评分匹配分析

阅读:1

Abstract

BACKGROUND: This study aimed to investigate the prognostic impact of intrapulmonary lymph node (ILN, stations 13-14) dissection on disease-free survival (DFS) in stage IA non-small cell lung cancer (NSCLC) patients in order to facilitate a more suitable determination of surgical strategies for early-stage cases. METHODS: We retrospectively analyzed 416 patients with pathological stage IA NSCLC from February 2016 to November 2019. The patients were divided into a group with ILN dissection (ILN(D+) group) and a group without ILN dissection (ILN(D-) group). DFS was compared using the Kaplan-Meier method and compared statistically using the log-rank test before and after propensity score matching (PSM). Subgroup analysis of DFS stratified based on tumor size was also calculated. RESULTS: Both before and after PSM, the four-year DFS of the ILN(D+) group was greatly increased compared to that of ILN(D-) group (90.1% vs. 79.7%, p = 0.003; 95.5% vs. 80.6%, p = 0.003, respectively) and multivariable cox regression analysis revealed ILN dissection was an independent factor favoring DFS in stage IA NSCLC (p = 0.016 and p = 0.015, respectively). Subgroup analysis revealed the four-year DFS was comparable between the ILN (D+) and ILN(D-) groups with regard to tumor size ≤1.5 cm (90.6% vs. 92.7%, p = 0.715). However, the ILN (D+) group was found to have a better oncological outcome compared with the ILN(D-) group with regard to tumor size >1.5 cm (90.0% vs. 73.8%, p = 0.003). CONCLUSIONS: The prognostic impact of ILN dissection on patients with stage IA NSCLC appears to be significantly influenced by tumor size, and this should be taken into account when choosing the most appropriate therapeutic modality.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。